Quiero saber acerca de...

40861

Federal Register / Vol. 86, No. 143 / Thursday, July 29, 2021 / Notices ANNUALIZED BURDEN HOUR TABLE
Average burden per response
Total burden hours
Subpart B, 46.207
Subpart C, 46.306 iii and iv
Subpart D, 46.407

3
3 4

1
1 1

1
1 1

3
3 4

Total

10

Sherrette A. Funn, Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.
FR Doc. 202116159 Filed 72821; 8:45 am
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.
ACTION: Notice.
AGENCY:

The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability ACBTSA will hold a virtual meeting. The meeting will be open to the public. The committee will discuss recommendations to improve the supply chain and data infrastructure that supports the blood industry, especially during public health emergencies. To facilitate this discussion, key stakeholders from across the nation and around the world will present on hemovigilance, preparedness, inventory management systems and other relevant issues.
DATES: The meeting will take place virtually on Tuesday, August 17, 2021
from approximately 10:00 a.m.6:00
p.m. and Wednesday, August 18, 2021
from approximately 10:00 a.m.6:00
p.m. Eastern Time ET. Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https
www.hhs.gov/oidp/advisory-committee/
blood-tissue-safety-availability/
meetings/2021-08-17/index.html when this information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human SUMMARY:

VerDate Sep<11>2014

19:19 Jul 28, 2021

Jkt 253001

Services, Mary E. Switzer Building, 330
C Street SW, Suite L600, Washington, DC 20024. Email: ACBTSA@hhs.gov.
ACBTSA
is a discretionary Federal advisory committee. ACBTSA The Committee is governed by the provisions of the Federal Advisory Committee Act FACA, Public Law 92463, as amended 5 U.S.C. App, which sets forth standards for the formation and use of advisory committees. On the day of the meeting, please go to https
www.hhs.gov/live/index.html to view the meeting. The public will have an opportunity to present their views to the ACBTSA orally during the meetings public comment session or by submitting a written public comment.
Comments should be pertinent to the meeting discussion. Persons who wish to provide verbal or written public comment should review instructions at https www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2021-08-17/
index.html and respond by midnight August 9, 2021, ET. Verbal comments will be limited to three minutes each to accommodate as many speakers as possible. Written public comments will be accessible to the public on the ACBTSA web page prior to the meeting.
ACBTSA functions to provide advice to the Secretary through the Assistant Secretary for Health on a range of policy issues to include: 1 Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; 2 identification of public health issues that affect availability of blood, blood products, and tissues; 3 broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; 4 the impact of various economic factors e.g., product cost and supply on safety and availability of blood, blood products, and tissues; 5 risk communications related to blood transfusion and tissue transplantation; and 6 identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met
SUPPLEMENTARY INFORMATION:

BILLING CODE 415036P

jbell on DSKJLSW7X2PROD with NOTICES

Number of responses per respondents
Number of respondents
45 CFR part 46HHS consultation process provision
PO 00000

Frm 00060

Fmt 4703

Sfmt 4703

regularly since its establishment in 1997.
Dated: July 23, 2021.
James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy.
FR Doc. 202116120 Filed 72821; 8:45 am BILLING CODE 415028P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel;
Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia FH.
Date: September 2, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Bethesda, MD 20817 Virtual Meeting.
Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208
Z, Bethesda, MD 20892, 301 8277987, susan.sunnarborg@nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung
E:FRFM29JYN1.SGM

29JYN1